Operator

Good afternoon, and welcome to Poolbeg Pharma PLC Full Year Results Investor Presentation. [Operator Instructions]

I'd now like to hand you over to Jeremy Skillington, CEO. Good afternoon, sir.

Jeremy Skillington
CEO & Director

Good afternoon, and thank you for the introduction. I appreciate everybody joining us this late afternoon. Finally, a bit of a sunny Dublin. It's -- bleak winter is over.

And we're delighted here to be able to present on the back of our full year results announced this morning, company update, company presentation and let you know where we are with particularly POLB 001 clinical trials. So again, appreciate you joining us this evening. And I'll be sharing presentation duties tonight with Liam Tremble, our Principal Scientist, who will talk more of the POLB 001 clinical trial attributes.

So just to give a setting, just a grounding, a reminder, Poolbeg, we're a clinical-stage company developing POLB 001 that we believe has the potential to transform the lives of cancer patients by delivering these cancer immunotherapies in particular safely and locally. There's a big unmet need. There's a lot of issues around Cytokine Release Syndrome associated with cancer immunotherapies, and we believe we have a solution for that. We'll talk a little bit more about the scientific and medical rationale for that later on.

We're also developing an oral medication for obesity treatment, we'll touch upon later on as an oral GLP-1. Again, very exciting space to be in.

We are an AIM listed company, listed in London. And we believe we've got a strong investment case. We've got a terrific team here behind us, both on the, as I said, the clinical business